Stock TAK TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Takeda Pharmaceutical Company Limited Nyse

Equities

TAK

US8740602052

Real-time Estimate Cboe BZX
Other stock markets
 08:45:22 21/06/2024 pm IST 		5-day change 1st Jan Change
12.68 USD +0.52% Intraday chart for Takeda Pharmaceutical Company Limited -3.13% -11.07%
08:50am Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes MT
07:47am Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India RE

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Les sorcières épouvantent l'IA
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes
En Direct des Marchés : LVMH, Accor, Alstom, Atos, Casino, Plastivaloire, Boeing, Geberit...
Borsa di Italia: Le streghe terrorizzano l'AI
Bolsa de Madrid: Las brujas aterrorizan a la IA
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India
Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (PIDC)
Takeda presenta datos de largo plazo del ensayo clínico de fase 3 ADVANCE-CIDP 3 de HYQVIA® en pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC) en la Reunión Anual de la PNS
Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting
Sector Update: Health Care Stocks Decline Premarket Monday
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints
Takeda's seizure drug fails to meet main goal in late-stage studies
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. TAK Stock
  5. News Takeda Pharmaceutical Company Limited
  6. Other languages